Topical Spironolactone for Female Pattern Hair Loss: Does It Work?

Female pattern hair loss (FPHL) is one of the most common causes of hair thinning in women, affecting roughly half of women over their lifetime.

One of the most widely used medical treatments is spironolactone, an antiandrogen medication that can reduce the effect of androgens on susceptible hair follicles.

Most spironolactone used for female pattern hair loss is taken orally, and that is where the strongest evidence lies; but topical spironolactone for hair loss is attracting increasing interest, particularly for women who cannot tolerate oral treatment or want to minimise systemic exposure.

So does topical spironolactone actually work?

The short answer is that oral spironolactone still has the stronger evidence base. Topical spironolactone is a reasonable alternative in selected women, but the evidence suggests it works better when combined with topical minoxidil than when used alone.

Here is what the research actually shows.

How does spironolactone work in female pattern hair loss?

Female pattern hair loss is characterised by progressive miniaturisation of susceptible hair follicles. Over time, thick terminal hairs become progressively finer and shorter.

Androgens can contribute to this process in genetically susceptible women, even when blood androgen levels are within the normal range.

Spironolactone has antiandrogen effects. It blocks androgen receptors and reduces androgen signalling within androgen-sensitive tissues.

In hair loss treatment, the aim is therefore different from minoxidil.

Minoxidil primarily stimulates hair growth and prolongs the growth phase of the follicle, whereas spironolactone aims to reduce the androgen signalling that can drive follicular miniaturisation.

This difference in mechanism is one reason the two treatments are often used together.

Does oral spironolactone work for female pattern hair loss?

The evidence for oral spironolactone in female pattern hair loss is substantially stronger than the evidence for topical treatment.

A 2023 meta-analysis pooling four studies involving 192 patients found an overall improvement rate of 56.6% with oral spironolactone.

When spironolactone was combined with other treatments such as minoxidil, the improvement rate increased to 65.8%, compared with 43.2% with spironolactone monotherapy [1].

Individual studies also show a consistent benefit. In the study by Sinclair et al., 80 women were followed for an average of 16 months while taking spironolactone 200 mg daily. Around 80% experienced either improvement or stabilisation of their female pattern hair loss [2].

In another study by Famenini et al., involving women taking an average dose of approximately 110 mg daily, 74.3% reported improvement or stabilisation [3].

A 2022 systematic review by James and colleagues found that 49.3% of patients treated with spironolactone monotherapy achieved improved follicular density. The authors concluded that the strongest clinical results tended to occur with doses of 100 mg daily or above when treatment was continued for more than one year [4].

More recently, a 2026 retrospective comparative study involving 187 women followed for 24 months found that 54.4% of patients receiving spironolactone achieved at least a one-grade improvement on the Sinclair scale. Higher-dose spironolactone, with a median dose of around 130 mg daily, performed better than the maximum dose of the comparator drug bicalutamide in this study [5].

Taken together, these studies support oral spironolactone as an effective treatment option for appropriately selected women with female pattern hair loss.

Does spironolactone have to be given at a high dose?

Not necessarily.

Higher doses may produce a stronger antiandrogen effect, but they can also increase the likelihood of systemic side effects. There is also evidence that lower-dose spironolactone can be effective when combined with minoxidil.

In one prospective study, 100 women were treated with spironolactone 25 mg daily together with low-dose oral minoxidil 0.25 mg daily. Hair shedding and hair density scores improved progressively over 12 months [6].

This is important because it suggests that combination treatment may sometimes allow clinicians to use lower doses of individual drugs rather than relying on high-dose spironolactone alone.

Treatment therefore needs to be individualised according to the pattern and severity of hair loss, other medical conditions and the patient’s tolerance of treatment.

What are the side effects of oral spironolactone?

Oral spironolactone is generally well tolerated, but it is a systemic medication and therefore has potential side effects. Pooled data from 216 patients receiving oral spironolactone found the most commonly reported adverse effects included; menstrual disturbance (7.9%), dizziness or headache (6.5%), scalp itching (3.7%), rash (2.3%). Only around 3.2% of patients discontinued treatment because of side effects [6].

Interestingly, side effects were significantly more frequent at doses of 80–110 mg daily than at 25 mg daily.Other recognised concerns with oral spironolactone include low blood pressure, increased potassium levels and potential effects in pregnancy.

This is where topical spironolactone becomes particularly interesting.

What is topical spironolactone?

Topical spironolactone is spironolactone formulated into a solution, cream or gel that is applied directly to the scalp. The aim is to deliver antiandrogen activity closer to the hair follicle while reducing systemic exposure.

There is currently no FDA-approved topical spironolactone treatment for female pattern hair loss, so formulations used in studies and clinical practice are generally compounded or investigational. Concentrations also vary considerably between studies, commonly ranging from around 1% to 5%. This lack of standardisation is important when interpreting the evidence.

Does topical spironolactone work for female pattern hair loss?

There is evidence that it can work, although the number and quality of studies are still much smaller than for oral spironolactone or topical minoxidil.

A 2021 study published in Dermatologic Therapy compared topical minoxidil 5%, topical spironolactone 1% and a combination of topical minoxidil and spironolactone. Treatment continued for 12 months, with patients also undergoing scalp biopsies before and after treatment. Topical spironolactone alone produced a clinical response in approximately 80% of patients, compared with approximately 90% with topical minoxidil [7].

Importantly, the scalp biopsies also demonstrated biological changes within the follicles. There was an increase in hairs in the active anagen growth phase and reductions in telogen hairs and miniaturised vellus hairs.

Is topical spironolactone as effective as minoxidil?

Probably not when used on its own.

A trial comparing topical finasteride 1%, topical spironolactone 5% and topical minoxidil 5% in women with female pattern hair loss found that topical spironolactone monotherapy was the weakest of the three treatments on clinical and trichoscopic assessment [8]. That is an important finding. Topical spironolactone may have a role, but the current evidence does not support replacing topical minoxidil with spironolactone in most women.

The more interesting question is whether the two should be combined.

Does topical spironolactone work better with minoxidil?

This is where the evidence becomes particularly insightful. Across several studies, topical spironolactone combined with topical minoxidil has performed better than either treatment used alone.

In the 2021 study described above, the combination of minoxidil and spironolactone produced the strongest clinical and histological response of the three treatment groups [7]. Another study assessed a combined spironolactone 5% and minoxidil 5% solution. Compared with minoxidil alone, the combination produced a reduction in miniaturised vellus hairs and an increase in new, upright regrowing hairs over 12 weeks [9].

A 2023 systematic review examining both oral and topical spironolactone in androgenetic alopecia also found a particularly strong efficacy signal when topical spironolactone was combined with minoxidil.

Across the included combination studies, approximately 95% of patients were classified as having an effective response [6]. The exact figure needs to be interpreted cautiously because the studies were relatively small and heterogeneous, but the overall pattern is consistent. Spironolactone appears to work better when paired with minoxidil (oral or topical) than when used alone.

Why might spironolactone and minoxidil work better together?

The combination makes biological sense because the drugs target different aspects of female pattern hair loss.

Minoxidil stimulates follicular growth, it helps prolong the anagen phase and can increase the size and activity of miniaturised follicles.

Spironolactone reduces androgen signalling; it targets one of the mechanisms contributing to progressive follicular miniaturisation.

In simple terms, minoxidil encourages the follicle to grow, while spironolactone may reduce one of the signals causing it to shrink. For some women, targeting both mechanisms may therefore produce a better result than either treatment alone.

Who might benefit from topical spironolactone?

Topical treatment may be particularly useful for women who:

1. cannot tolerate oral spironolactone
2. experience dizziness or low blood pressure with oral treatment
3. have concerns about systemic side effects
4. are unsuitable for systemic antiandrogen treatment
5. have not achieved sufficient improvement with topical minoxidil alone
6. prefer a topical rather than oral treatment approach.

It may also be considered as part of a combination topical treatment containing both spironolactone and minoxidil.

However, topical treatment should not be viewed as automatically safer or suitable for everybody simply because it is applied to the scalp. Systemic absorption may still occur, and pregnancy considerations remain important when using antiandrogen treatments.

Oral spironolactone vs topical spironolactone: which is better?

Based on the evidence currently available, oral spironolactone has the stronger evidence base and is likely to produce a more reliable antiandrogen effect.

Topical spironolactone is promising, but the evidence is still more limited. I therefore tend to think of topical spironolactone not as a direct replacement for oral treatment, but as another option within a personalised treatment plan.

For a woman who can tolerate oral spironolactone and has no contraindications, oral treatment remains the better-established route. For a woman who cannot or does not want to use systemic treatment, topical spironolactone becomes a reasonable alternative.

If topical spironolactone is being used, the evidence currently suggests that combining it with topical minoxidil makes more sense than using it alone.

My practical take

In my experience as a dermatologist treating female pattern hair loss for over two decades, it is rarely managed successfully with a one-size-fits-all approach.

The strongest evidence for spironolactone in female pattern hair loss still lies with oral treatment, particularly when used at an appropriate dose and continued for long enough.

Topical spironolactone is an interesting and evolving option. It may be useful for women who cannot tolerate oral spironolactone, are unsuitable for systemic treatment, or simply prefer a topical approach.

The most convincing signal in the topical literature is not spironolactone used alone. It is topical spironolactone combined with topical minoxidil. That combination targets female pattern hair loss from two different directions: stimulating follicular growth while reducing androgen-driven miniaturisation.

There are, however, important limitations. There is currently no standardised approved topical spironolactone formulation, concentrations vary between studies, and many of the published trials remain small.

We therefore need larger, well-designed randomised trials before topical spironolactone can be placed on the same evidence footing as established treatments such as topical minoxidil.

For now, I see it as a useful additional tool rather than a replacement for the treatments we already know work.

#FemalePatternHairLoss #HairLoss #Spironolactone #Minoxidil #Dermatology #WomensHealth

References

1. Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023;15(8). doi:10.7759/cureus.43559
2. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466-473.
3. Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol. 2015;73(4):705-706.
4. James JBF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. J Am Acad Dermatol. 2022;86(2):425-429.
5. Spironolactone versus bicalutamide for female pattern hair loss: a 24-month unicenter retrospective comparative study of effectiveness and safety. Dermatol Ther (Heidelb). PubMed ID 42565959.
6. Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol. 2023;16:603-612. doi:10.2147/CCID.S398950 (includes citation to Sinclair R. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018.)
7. Abdel-Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel-Aziz RTA. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021;34(1). doi:10.1111/dth.14678
8. Clinical and trichoscopic evaluations of topical finasteride 1%, topical spironolactone 5%, and minoxidil 5% in female pattern hair loss treatment. Dermatol Pract Concept.
9. Ammar AM, Elshahid AR, Abdel-Dayem HA, et al. Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: a cross-sectional comparative study. J Cosmet Dermatol. 2022;21(11):5790-5799. doi:10.1111/jocd.15328

https://www.linkedin.com/pulse/topical-spironolactone-female-pattern-hair-loss-does-work-iaisha-ali-k5dme